No Prescription |
 |
 | ||
|
Xatral Uroxatral |
|
| ||
No Prescription » Prescription Drugs 17 » Xatral Uroxatral This medication is used to treat the symptoms of a prostate gland condition called BPH (benign prostatic hyperplasia also known as enlarged prostate). It is an alpha blocker that works by relaxing the muscles in the bladder neck and prostate. Relaxing these muscles leads to relief of symptoms of BPH such as the feeling of needing to urinate frequently or urgently difficulty in beginning the flow of urine weak stream and the need to urinate during the middle of the night.This medication should not be used to treat high blood pressure. Buy Xatral Uroxatral and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Xatral Uroxatral: Product Type: Prescription Drugs 17 Xatral ( Uroxatral Generic Alfuzosin ) Xatral (Uroxatral Generic Alfuzosin) Uroxatral Generic Alfuzosin 10mg Uroxatral Generic Alfuzosin Xatral
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
